SELLAS Life Sciences is a late-stage clinical-stage biotech company developing GPS (WT1-targeting immunotherapy) and SLS009 (CDK9 inhibitor) primarily for AML and other cancers, with a pivotal Phase 3 REGAL trial readout imminent, substantial recent cash inflows extending runway, highly volatile stock performance driven by trial news, and mixed but generally positive analyst views on upside potential amid pending binary events.[web:9][web:0]
Data Limitation: Company history details primarily from IR site and profiles as of mid-2026; exact founding nuances vary slightly across sources (2012 vs. 2006 predecessor entities).
Links for more information: Company Website | Investor Relations | Latest News
SLS has exhibited extreme volatility typical of clinical-stage biotechs, with massive gains over multi-year periods driven by trial progress and financing news, offset by drawdowns.
Interpretation: Performance heavily tied to binary clinical catalysts (e.g., REGAL readout) and financing; retail-driven momentum evident in recent surges ahead of milestones.
Uncertainty: Exact future trajectory depends on trial outcomes, which remain blinded.
Links for more information: Yahoo Finance Historical Data | Macrotrends History | Company Stock Info
| Metric | Q1 2026 (ended Mar 31, 2026) | FY 2025 (ended Dec 31, 2025) |
|---|---|---|
| Cash & Cash Equivalents | $107.1 million (+$7.5M warrant proceeds in Q2 to date) | $71.8 million (+$42.6M warrant proceeds in Q1 2026) |
| Net Loss | ~$8.4 million (EPS ~$0.05 miss estimates) | $26.9 million (EPS $0.25) |
| R&D Expenses | Higher (advancing trials) | Significant portion of spend |
| Revenue | None (clinical-stage) | None |
| Shares Outstanding | ~186-197 million (variable with exercises) | Similar |
No product revenue; funded primarily via equity/warrants. Cash runway extended significantly (estimates into 2028 in some analyses).
Interpretation: Strengthened balance sheet reduces near-term dilution risk ahead of catalysts; typical pre-commercial burn rate.
Data Limitation/Assumption: Financials from company press releases (Q1/FY2025 reports); exact Q2 2026 updates not available in sources; EPS comparisons based on analyst estimates at time of reporting. Market cap fluctuates with stock price (not shown here).
Links for more information: Q1 2026 Earnings Release | FY 2025 Earnings Release | Yahoo Finance Financials
Analyst coverage is limited (typically 1-3 firms); consensus varies by source and recency due to small analyst pool and stock volatility.
| Source/Date | Rating | Price Target | Notes |
|---|---|---|---|
| Maxim Group (Mar 2026) | Buy (maintained/raised) | $25.00 (or up to $30 high) | Positive on pipeline and catalysts |
| Alliance Global / others | Buy / Strong Buy | $25 (raised from $10) | REGAL milestones cited |
| Consensus (multiple aggregators) | Strong Buy or Buy (2 analysts) | Avg. $27.50 (range $25-$30) | Implied significant upside |
| MarketBeat / others | Hold (mixed; 2 Buy, 1 Sell in some tallies) | $10.00 | Lower targets in older/mixed views |
Interpretation: Bullish views emphasize imminent REGAL readout and dual pipeline; lower targets reflect risks of clinical failure or dilution.
Uncertainty: Ratings can shift rapidly with news; limited number of analysts means high variability across platforms.
Data Limitation: Aggregated from Yahoo, MarketBeat, WSJ, Benzinga, etc.; specific dates range from late 2025 to mid-2026; not all firms actively covering post-price surges.
Links for more information: Yahoo Analyst Page | MarketBeat Ratings | Benzinga Ratings
Interpretation: Partnerships de-risk development and provide non-dilutive capital/milestones; success hinges on regulatory approval and commercialization partnerships.
Links for more information: Company Pipeline/Partners | IR Overview
Primarily other clinical-stage oncology biotechs targeting AML, hematologic malignancies, or immunotherapies/CDK inhibitors. No direct head-to-head approved competitors for GPS/SLS009 yet.
| Competitor | Focus Area | Comparison Notes |
|---|---|---|
| Jazz Pharmaceuticals | AML/hematologic oncology | Commercial products; larger scale |
| Adaptimmune Therapeutics | Cancer immunotherapies (T-cell) | Similar immunotherapy approach |
| CRISPR Therapeutics / Sana Biotechnology | Gene editing / cell therapies for cancer | Advanced modalities; broader pipelines |
| Syros Pharmaceuticals / others | CDK inhibitors / AML targeted therapies | Overlaps in CDK9/AML space |
| Marker Therapeutics, Immix Biopharma, TME Pharma | Oncology immunotherapies | Smaller peers in niche |
Broader competitive landscape includes ~3,300+ oncology biotechs (many funded/exited).
Interpretation: SELLAS differentiates via WT1 specificity (GPS) and selective CDK9 profile (SLS009); combination potential with checkpoint inhibitors is a strength.
Data Limitation: Competitor list not exhaustive; dynamic industry with frequent M&A; based on profile comparisons as of 2026.
Links for more information: PitchBook Competitors | Tracxn Profile